TOP > 外国特許検索 > Method for screening substances capable of promoting immune response through inhibition of cd22 function in b cells

Method for screening substances capable of promoting immune response through inhibition of cd22 function in b cells

外国特許コード F110003664
整理番号 A261-09WO
掲載日 2011年6月30日
出願国 欧州特許庁(EPO)
出願番号 07851040
公報番号 2098246
公報番号 2098246
出願日 平成19年12月21日(2007.12.21)
公報発行日 平成21年9月9日(2009.9.9)
公報発行日 平成29年6月28日(2017.6.28)
国際出願番号 JP2007074634
国際公開番号 WO2008078673
国際出願日 平成19年12月21日(2007.12.21)
国際公開日 平成20年7月3日(2008.7.3)
優先権データ
  • 特願2006-349458 (2006.12.26) JP
  • 2007WO-JP74634 (2007.12.21) WO
発明の名称 (英語) Method for screening substances capable of promoting immune response through inhibition of cd22 function in b cells
発明の概要(英語) (EP2098246)
The purpose of the present invention is to elucidate a relationship between deregulation of signaling by CD22 and a rapid response of B cells by IgG-BCR and the like, and to provide a method capable of inducing a rapid immune response and defending against infection instead of vaccine.
The present invention relates to a method for promoting an immune response causing such a strong proliferation of clones and production of a large amount of antibody-producing cells as those seen in the memory immune response even in the naive B cells expressing IgM-BCR and IgD-BCR by inhibiting The CD22 function in B cells; and to a method for screening a substance capable of promoting the immune response based on a change in the CD22 function in B cells.
特許請求の範囲(英語) [claim1]
1. An in vitro screening method for screening a substance capable of increasing proliferation and survival of B cells in an early stage of the immune response, wherein the method is based on determining the degree of inhibition of the expression of the CD22 gene in IgM and IgD positive naive B cells, wherein said method comprises the following steps: (a) contacting, in vitro, a substance to be screened with IgM and IgD positive naive B cells; (b) detecting the degree of inhibition of the expression of the CD22 gene in said cells; and (c) selecting a substance which inhibits said expression, and wherein the early stage of the immune response is from the first to the seventh day after an immunization.
[claim2]
2. A non-therapeutic method for screening a substance capable of increasing proliferation and survival of B cells in an early stage of the immune response, wherein the method is based on determining the degree of inhibition of the expression of the CD22 gene in IgM and IgD positive naive B cells, wherein said method comprises the following steps: (a) contacting a substance to be screened with IgM and IgD positive naive B cells; (b) detecting the degree of inhibition of the expression of the CD22 gene in said cells; and (c) selecting a substance which inhibits said expression, wherein the early stage of the immune response is from the first to the seventh day after an immunization,
and wherein if said method is carried out in vivo, the subject is non-human.
[claim3]
3. A method according to Claim 1 or 2, wherein the early stage of the immune response is from the third to fifth day after an immunization.
[claim4]
4. A method according to Claim 1, 2 or 3, wherein increasing proliferation and survival of B cells comprises the increase of proliferation, division and/or survival of the B cells in the early stage of the immune response.
[claim5]
5. A method according to Claim 4, wherein the B cells proliferate and/or divide into IgG1 **+ B cells, IgM **+ B cells and germinal center B cells.
[claim6]
6. A method according to Claim 1, 2 or 3, wherein increasing proliferation and survival of B cells comprises class switching and/or differentiation of the B cells in an earlier stage.
[claim7]
7. A method according to Claim 6, wherein the class switching is that to IgG1 **+ positive cells and/or the differentiation is that into antibody-producing cells or germinal center B cells.
[claim8]
8. A method according to Claim 1, 2 or 3, wherein increasing proliferation and survival of B cells comprises an increase in the number of antibody-producing cells and in the amount of antibodies produced and/or the production of antibodies in an earlier stage.
[claim9]
9. A method according to any one of Claims 1 to 8, wherein the expression of the CD22 gene is repressed at a transcriptional level.
[claim10]
10. A method according to any one of Claims 1 to 8, wherein said inhibition is related to the promotion of signal transduction of B cell receptor.
  • 出願人(英語)
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • TSUBATA TAKESHI
  • ONODERA TAISHI
国際特許分類(IPC)
欧州特許分類/主・副
  • A61K039/00
  • C12N005/06B11B
  • G01N033/50D2F2D
  • S01N333/705B
指定国 (EP2098246)
Contracting States: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
参考情報 (研究プロジェクト等) CREST Clarification of the Biological Functions of Sugar Chains and the Use of this Knowledge in Applied Technologies AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close